Assessing the efficacy of celecoxib after tonsillectomy and/or adenoidectomy: A systematic review and meta‐analysis of randomised control trials
Clinical Otolaryngology · 2024
DOI: 10.1111/coa.14177 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Otolaryngology, 2024. Verfasst von Umm E Salma Shabbar Banatwala und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Adenoidectomy, Celecoxib, Cyclooxygenase 2 Inhibitors, Postoperative Pain. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objectives
Tonsillectomy and adenoidectomy are common surgical procedures that cause persistent pain, bleeding, and functional limitations. We aimed to investigate the efficacy of celecoxib compared with a placebo for managing post‐tonsillectomy or adenoidectomy pain and other adverse events.
Design
Systematic review and meta‐analysis.
Methods
We conducted a systematic literature search in the PubMed, Cochrane, and Google Scholar databases from inception until July 2023. Dichotomous outcomes have been reported as risk ratios (RR) while continuous outcomes were reported using mean differences (MD). A funnel plot was drawn to investigate publication bias.
Results
From 1394 records identified, 6 randomised double‐blind trials comprising 591 participants undergoing tonsillectomy and/or adenoidectomy were eligible for inclusion. A high dose (400 mg) of celecoxib was effective in decreasing the pain score for ‘worst pain’ after the procedure (MD: −10.98, [95% CI: −11.53, −10.42], p < .01, I 2 = 0%) while a low dose (200 mg) was not significantly effective ( p = 0.31). For managing other outcomes such as vomiting (RR: 1.37 [95% CI: 0.69, 2.68], p = 0.37, I 2 = 67%), diarrhoea (RR: 1.41, [95% CI: 0.75, 2.64], p = .29, I 2 = 42%), dizziness/drowsiness (RR: 0.90, [95% CI: 0.71, 1.15], p = .48, I 2 = 0%), functional recovery time ( p = .74), and headache ( p = .91), there was no significant difference between the group on celecoxib and the placebo group regardless of dosage. Finally, there was no significant difference (RR: 1.02, [95% CI: 0.91, 1.15], p = .69, I 2 = 0%) in the effect of the intervention on minimum bleeding, moderate bleeding, and profuse bleeding.
Conclusion
This meta‐analysis provides robust evidence pooled from high‐quality trials and raises questions about the efficacy of celecoxib for tonsillectomy and/or adenoidectomy, challenging existing perceptions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
- Jinnah Sindh Medical University, Karachi, Pakistan.
- Peoples University of Medical and Health Sciences for Women, Nawabshah, Pakistan.
- Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan.
ORCID-Profile: Umm E Salma Shabbar Banatwala, Abdul Rehman Shah Syed
Zitieren
APA
Banatwala, U. E. S. S., Syed, A. R. S., Ain, N. U., Zulfikar, A., Akhund, I. I., Lodhi, R., Baig, R., Ghufran, L., Rizwan, A., Bai, M., Khatri, M., & Kumar, S. (2024). Assessing the efficacy of celecoxib after tonsillectomy and/or adenoidectomy: A systematic review and meta‐analysis of randomised control trials. Clinical Otolaryngology. https://doi.org/10.1111/coa.14177
Vancouver
Banatwala UESS, Syed ARS, Ain NU, Zulfikar A, Akhund II, Lodhi R, et al. Assessing the efficacy of celecoxib after tonsillectomy and/or adenoidectomy: A systematic review and meta‐analysis of randomised control trials. Clinical Otolaryngology. 2024. doi:10.1111/coa.14177
BibTeX
@article{Banatwala2024,
author = {Banatwala, Umm E Salma Shabbar and Syed, Abdul Rehman Shah and Ain, Noor Ul and Zulfikar, Aimen and Akhund, Ilqa Ikram and Lodhi, Rija and Baig, Rameesha and Ghufran, Laiba and Rizwan, Ayesha and Bai, Meena and Khatri, Mahima and Kumar, Satesh},
title = {Assessing the efficacy of celecoxib after tonsillectomy and/or adenoidectomy: A systematic review and meta‐analysis of randomised control trials},
journal = {Clinical Otolaryngology},
year = {2024},
doi = {10.1111/coa.14177}
}
EUVIMED